Express News | Black Diamond Therapeutics Expects Cash & Equivalents Of $115.2M As Of March-End To Be Sufficient To Fund Operations Into Q3 Of 2025
Express News | Black Diamond Therapeutics Inc: Cash, Cash Equivalents, and Investments of $115.2 Mln as of March 31, 2024
Black Diamond Theraptcs 1Q Research and Development Expenses $13.5M >BDTX
Black Diamond Theraptcs 1Q Research and Development Expenses $13.5M >BDTX
Express News | Black Diamond Therapeutics Q1 Net Income USD -18.225 Million
Express News | Black Diamond Therapeutics Q1 Operating Expenses USD 20.246 Million
Express News | Black Diamond Therapeutics Q1 Basic EPS USD -0.35
Express News | Black Diamond Therapeutics Q1 Income From Operations USD -20.246 Million
Press Release: Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update -- Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024
Black Diamond Therapeutics | 10-Q: Quarterly report
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
PDF Version Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024Enrollment ongoing in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC; ini
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
PDF Version CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target fa
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday's after-market session. The market value of their outstanding shares is at $1.7 million. ABVC BioPharma (NAS
Garry Menzel Joins GHO Capital as Operating Partner
Garry Menzel joins GHO Capital as Operating Partner Former CEO of TCR2 Therapeutics with significant investment and operating experience to support deal origination and provide best in class services to pioneering
Black Diamond Therapeutics Announces Changes to Board of Directors
PDF Version CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target fa
Black Diamond Therapeutics (BDTX) Gets a Buy From Piper Sandler
Black Diamond Theraptcs Is Maintained at Outperform by Wedbush
Black Diamond Theraptcs Is Maintained at Outperform by Wedbush
Black Diamond Therapeutics Says BDTX-1535 Potentially Inhibits Non-Classical Mutations in Non-Small Cell Lung Cancer Patients
Black Diamond Therapeutics (BDTX) said Sunday that preclinical data showed that BDTX-1535 potentially inhibits non-classical mutations in non-small cell lung cancer patients. Real-world data showed no
Black Diamond Therapeutics Presented Novel Real-World Evidence Of The Evolving EGFR Mutation Landscape In NSCLC And The Opportunity For BDTX-1535 In An Oral Presentation At The 2024 AACR Annual Meeting
Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLCEmerging data show non-classical EGFR mutations can be co-expressed with the classical L858R m
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
PDF Version Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLCEmerging data show non-classical EGFR mutations can be co-expressed with the
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
PDF Version CAMBRIDGE, Mass. and NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies t
No Data